Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7)

Jordi Rodón; Silvia Damian; Muhammad Furqan; Jesús García-Donas; Hiroo Imai; Antoine Italiano; Iben Spanggaard; Makoto Ueno; Tomoya Yokota; Maria Luisa Veronese; Natalia Oliveira; Xin Li; Aidan Gilmartin; Michael Schaffer; Lipika Goyal

doi:10.1038/s41591-024-03072-w

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7)

Jordi Rodón, Silvia Damian, Muhammad Furqan, Jesús García-Donas, Hiroo Imai, Antoine Italiano, Iben Spanggaard, Makoto Ueno, Tomoya Yokota, Maria Luisa Veronese, Natalia Oliveira, Xin Li, Aidan Gilmartin, Michael Schaffer, Lipika Goyal^*

^*Corresponding author for this work

Department of Oncology

Original language	English
Publication date	Aug 2024
Volume	30
DOIs	https://doi.org/10.1038/s41591-024-03072-w
Publication status	Published - Aug 2024

Series	Nature Medicine
ISSN	1078-8956

Access to Document

10.1038/s41591-024-03072-w

Cite this

Rodón, J., Damian, S., Furqan, M., García-Donas, J., Imai, H., Italiano, A., Spanggaard, I., Ueno, M., Yokota, T., Veronese, M. L., Oliveira, N., Li, X., Gilmartin, A., Schaffer, M., & Goyal, L. (2024, Aug). Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7). Nature Medicine https://doi.org/10.1038/s41591-024-03072-w

Rodón, J, Damian, S, Furqan, M, García-Donas, J, Imai, H, Italiano, A, Spanggaard, I, Ueno, M, Yokota, T, Veronese, ML, Oliveira, N, Li, X, Gilmartin, A, Schaffer, M & Goyal, L 2024, Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7).. https://doi.org/10.1038/s41591-024-03072-w

@misc{f0238faafd0147a98dcd251d1eac080c,

title = "Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7)",

author = "Jordi Rod{\'o}n and Silvia Damian and Muhammad Furqan and Jes{\'u}s Garc{\'i}a-Donas and Hiroo Imai and Antoine Italiano and Iben Spanggaard and Makoto Ueno and Tomoya Yokota and Veronese, {Maria Luisa} and Natalia Oliveira and Xin Li and Aidan Gilmartin and Michael Schaffer and Lipika Goyal",

year = "2024",

month = aug,

doi = "10.1038/s41591-024-03072-w",

language = "English",

volume = "30",

series = "Nature Medicine",

publisher = "Nature Publishing Group",

type = "Other",

}

TY - GEN

T1 - Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7)

AU - Rodón, Jordi

AU - Damian, Silvia

AU - Furqan, Muhammad

AU - García-Donas, Jesús

AU - Imai, Hiroo

AU - Italiano, Antoine

AU - Spanggaard, Iben

AU - Ueno, Makoto

AU - Yokota, Tomoya

AU - Veronese, Maria Luisa

AU - Oliveira, Natalia

AU - Li, Xin

AU - Gilmartin, Aidan

AU - Schaffer, Michael

AU - Goyal, Lipika

PY - 2024/8

Y1 - 2024/8

UR - http://www.scopus.com/inward/record.url?scp=85194247032&partnerID=8YFLogxK

U2 - 10.1038/s41591-024-03072-w

DO - 10.1038/s41591-024-03072-w

M3 - Other contribution

C2 - 38789647

VL - 30

T3 - Nature Medicine

ER -

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial(Nature Medicine, 10.1038/s41591-024-02934-7)

Access to Document

Other files and links

Cite this